Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14238831 | 0.93 | FGFR3 (0.58) | FGFR3 | |
| SCHEMBL14212790 | 0.93 | FGFR3 (0.61) | FGFR3 | |
| SCHEMBL1126290 | 0.92 | FGFR3 (0.59) | FGFR3 | |
| SCHEMBL1126162 | 0.85 | FGFR3 (0.58) | FGFR3 | |
| SCHEMBL1126061 | 0.84 | FGFR3 (0.61) | FGFR3 | |
| SCHEMBL1126271 | 0.84 | FGFR3 (0.60) | FGFR3 | |
| SCHEMBL1126121 | 0.84 | FGFR3 (0.54) | FGFR3 | |
| SCHEMBL3315289 | 0.83 | FGFR3 (0.49) | FGFR3 | |
| SCHEMBL14212785 | 0.82 | FGFR3 (0.53) | FGFR3 | |
| SCHEMBL3315283 | 0.82 | FGFR3 (0.48) | FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210000951-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2021-01-07 | — | — | US | claimed |
| EP-3662903-A2 | COMBINATION THERAPIES | Novartis AG (CH) | 2020-06-10 | — | — | EP | claimed |
| EP-3200775-A2 | COMBINATION THERAPIES | Novartis AG (CH) | 2017-08-09 | — | — | EP | claimed |
| US-20170209574-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-07-27 | — | — | US | claimed |
| WO-2016054555-A2 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2016-04-07 | — | — | WO | claimed |
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | claimed |
| US-8674099-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | claimed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | claimed |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | claimed |
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | claimed |
| US-8273882-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | claimed |
| EP-2282995-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2011-02-16 | — | — | EP | claimed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | claimed |
| CN-118236374-A | Methods of modulating TIGIT and PD-1 signaling pathways using 1,2, 4-oxadiazole compounds | 奥瑞基尼肿瘤有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-12005045-B2 | Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compounds | AURIGENE ONCOLOGY LIMITED (IN) | 2024-06-11 | — | — | US | disclosed |
| US-20240122904-A1 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-04-18 | — | — | US | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | FGFR3 1515/4885 |
| US-20240122904-A1 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | PDCD1, CD274, PDCD1LG2 | FGFR3 234/4885 |
| US-20170209574-A1 | COMBINATION THERAPIES | CD274, CD40, CD58 | FGFR3 187/4885 |
| US-12005045-B2 | Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compounds | PDCD1, CD274, PDCD1LG2 | FGFR3 234/4885 |
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | FGFR3 763/4885 |
| US-20210000951-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | FGFR3 93/4885 |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | FGFR3 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.